Live from Open Targets Platform, fetched 2026-11-12 05:48 UTC. Every row links to its source record.

ITGB6 integrin subunit beta 6

ENSG00000115221 · protein coding · Open Targets profile

Integrin alpha-V:beta-6 (ITGAV:ITGB6) is a receptor for fibronectin and cytotactin (PubMed:17158881, PubMed:17545607). It recognizes the sequence R-G-D in its ligands (PubMed:17158881, PubMed:17545607). Internalization of integrin alpha-V/beta-6 via clathrin-mediated endocytosis promotes carcinoma cell invasion (PubMed:17158881, PubMed:17545607). ITGAV:ITGB6 acts as a receptor for fibrillin-1 (FBN1) and mediates R-G-D-dependent cell adhesion to FBN1 (PubMed:17158881). Integrin alpha-V:beta-6 (ITGAV:ITGB6) mediates R-G- D-dependent release of transforming growth factor beta-1 (TGF-beta-1) from regulatory Latency-associated peptide (LAP), thereby playing a key role in TGF-beta-1 activation (PubMed:15184403, PubMed:22278742, PubMed:28117447). {ECO:0000269|PubMed:15184403, ECO:0000269|PubMed:17158881, ECO:0000269|PubMed:17545607, ECO:0000269|PubMed:22278742, ECO:0000269|PubMed:25383667, ECO:0000269|PubMed:28117447}.

None of the 4 drugs recorded against ITGB6 is approved yet; 1 reached Phase 3

Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.

Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.

In 2 of 15 cancers, the evidence for ITGB6 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule: Structure with Ligand, High-Quality Ligand, Druggable Family
Antibody: Advanced Clinical, UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM

gnomAD loss of function constraint: o/e 0.9468299746513367 (upper bound 1.1403000354766846). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of ITGB6's approved or late-stage drugs in the last three years.

1 of 5 trials of drugs against ITGB6 have sites only in China

Registry trials of sigvotatug vedotin, abituzumab, STX-100 updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 1 of 5 have all sites in one country.

Sites only in this groupSites here and elsewhere

Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. Source: ClinicalTrials.gov, fetched live.

3 trials of drugs against ITGB6 were stopped early; 1 give no reason

Terminated, withdrawn and suspended interventional trials of sigvotatug vedotin, abituzumab, STX-100, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 3 most recent of 3.

Ph2NCT03688230 brief why it stopped
withdrawn · 2020-03-18 · SFJ Pharmaceuticals X, LTD. · abituzumab
“Co-development decision”
Ph2NCT02745145 brief why it stopped
terminated · 2019-06-18 · EMD Serono Research & Development Institute, Inc. · Abituzumab 1500 mg, Abituzumab 500 mg
“Difficulties experienced in identifying participants who meet the eligibility criteria of the trial.”
Ph2NCT00878761 brief why it stopped
withdrawn · 2011-05-23 · Stromedix, Inc. · STX-100
No reason given

Paediatric incentives and obligations for ITGB6's drugs

For sigvotatug vedotin, abituzumab, STX-100: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.

FDA pediatric target list: no · ITGB6 is not on the list
Rule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
EU paediatric investigation plan: no · No EMA paediatric investigation plan decision names sigvotatug vedotin, abituzumab, stx-100
Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
EU orphan designation: no · No EU orphan designation names sigvotatug vedotin, abituzumab, stx-100
Rule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
Authorised in the EU: no · EMA lists no centrally authorised medicine of sigvotatug vedotin, abituzumab, stx-100
Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the link
Rule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of sigvotatug vedotin, abituzumab, stx-100
Rule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
Registered studies open to children: no · No interventional study of sigvotatug vedotin, abituzumab, stx-100 includes patients under 18
Rule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12

Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs

All 4 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

Drug	Type	Highest stage	Indications	Source records
SIGVOTATUG VEDOTIN	Antibody drug conjugate	phase 3	non-small cell lung carcinoma, neoplasm	Open Targets · ChEMBL
ABITUZUMAB	Antibody	phase 2	colorectal cancer, prostate cancer, systemic sclerosis, interstitial lung disease, ovarian cancer	Open Targets · ChEMBL
STX-100	Unknown	phase 2	idiopathic pulmonary fibrosis	Open Targets · ChEMBL
SIGVOTATUG	Antibody	unknown	neoplasm	Open Targets · ChEMBL